JDJuliet M. Daniel

Juliet M. Daniel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juliet M. Daniel has a total of 259 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Kaiso overexpression promotes an interferon immune response in murine intestines

    by Lindyann R. Lessey, Hanad Adan, Shaiya C. Robinson, Roopali Chaudhary, Shruthilayaa Sivakumar, Stephanie Ali Fairbairn, Danial Mohammadi, Kyle Kim, Dereck Alleyne, Kathleen E. Houlahan, et al.

    The POZ-ZF transcription factor Kaiso plays important roles in vertebrate development and tumorigenesis and binds DNA with dual-specificity at both a consensus DNA sequence and methyl-CpG sites. In murine intestines, Kaiso overexpression induces a chronic inflammatory phenotype that involves NFκB signaling and neutrophil activation. However, a thorough understanding of the molecular mechanisms and signaling pathways involved in the Kaiso-induced inflammatory response warrant further investigation. In this study, global transcriptomes of ileal tissue from 6-week-old Kaiso overexpressing transgenic (KaisoTg) and non-transgenic (NonTg) control mice were generated by RNA sequencing and compared for differential gene expression prior to histologic inflammation. Functional analysis of differentially expressed genes identified an enrichment of genes involved in type I interferon immune response despite preserved epithelial architecture and the absence of neutrophil infiltration. Irf7, Isg15, Usp18 and Ifi44 were identified as key genes mediating type I interferon signaling in intestinal epithelial cells. We determined that Kaiso binds to and regulates the IRF7 promoter via the consensus Kaiso binding site (KBS). Additionally, promoter-reporter assays confirmed that Kaiso activated the minimal IRF7 promoter-reporter in a KBS-specific and methyl-CpG-independent manner. Collectively, our findings demonstrate that Kaiso overexpression activates a type I interferon gene program that precedes histologic inflammation and implicates IRF7 as a putative Kaiso target gene that mediates this response.


  • Open Access

    Kaiso modulates androgen receptor expression in triple-negative breast cancer

    by Stephanie Ali Fairbairn, Kyle Kim, Robert W. Cowan, Lindyann R. Lessey, Melody Fanaian, Hanad Adan, Sailaja Golamari, Ryan Rattan, Juliet M. Daniel

    Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that presents therapeutic challenges due to the lack of expression of biomarkers required for conventional targeted treatments. Although a subset of TNBC tumors respond to androgen receptor (AR) inhibitors, the majority exhibit low AR expression and poor outcomes. These AR-negative tumors have been subclassified as quadruple-negative breast cancer (QNBC). Notably, women of African ancestry (WAA) experience a disproportionate burden of TNBC and higher mortality compared to white women, a disparity not fully explained by socio-economic factors, thus suggesting a genetic susceptibility. The transcription factor Kaiso, previously implicated in TNBC progression and poor survival in WAA patients, may play a key role in QNBC biology. Expression profiling of TNBC tumors from WAA and white women was performed using publicly available datasets and tissue microarrays. To examine the role of Kaiso in AR regulation, we generated CRISPR-Cas9 Kaiso knockout TNBC cell lines and assessed AR expression using chromatin immunoprecipitation, immunoblotting, RT-qPCR and promoter-reporter assays. Cell viability, migration and invasion assays were used to evaluate the effect of Kaiso knockout on sensitivity to the AR inhibitor enzalutamide. High Kaiso expression combined with low AR expression correlated with poorer survival across breast cancer subtypes, including TNBC. WAA expressed significantly lower AR expression and a higher prevalence of the QNBC subtype. Kaiso associated with the endogenous AR promoter, and Kaiso knockout in TNBC cells increased AR expression while reducing ACSL4, an AR target gene that promotes metastasis through phospholipid remodeling. Notably, Kaiso knockout cells were more sensitive to enzalutamide compared to parental cells and reduced migration and invasion. Collectively, our findings implicate Kaiso as a key player in TNBC and QNBC, highlighting its potential as a druggable target for improving outcomes in these aggressive breast cancer subtypes.


  • Activation of STAT3 by cadherin engagement

    by Hanad Adan, Juliet Daniel, Leda Raptis

  • Open Access

    Kaiso (ZBTB33) engages with non-canonical binding motifs to regulate DNA damage responses in breast cancer cells

    by Maximillian Rätze, Milou Tenhagen, Juul Vollaers, Christopher Benner, Amit Mandoli, Abishek Singh, Myrthe Noordewier, Martin Hetzer, Joost Martens, Henk Stunnenberg, et al.

    In breast cancer, nuclear localization of Kaiso (ZBTB33), a dual specificity transcription factor, is a hallmark of high grade ductal-type carcinomas, especially in estrogen receptor negative disease. Regulation of gene expression by Kaiso is orchestrated via its engagement to distinct Kaiso binding sequence (KBS) motifs defined as canonical (cKBS; TCCTGCNA ) or CG-containing palindromic KBS (CG-KBS; TCTCGCGAGA ), depending on context. While there exists a clinical connection between localization of Kaiso expression and breast cancer, it remains unclear how Kaiso controls bi-modal canonical versus noncanonical transcriptional modulation. Here, we have combined Kaiso-specific chromatin immunoprecipitation (ChIP) and Kaiso-Dam methyltransferase identification (Dam-ID) approaches to map genomic Kaiso binding sites in breast cancer cells. We find that Kaiso mostly occupies the non-canonical CG-KBS sites in transcriptionally active and hypo-methylated (H3K4me3 and H3K27Ac enriched) promoter regions. Noncanonical CG-KBS targets are actively transcribed and linked to fast biological processes such as metabolism, cell cycle regulation and DNA damage repair. Functionally, we show that Kaiso expression is essential to prevent DNA damage in breast cancer cells. Loss of Kaiso leads to reduced expression of DNA damage response gene expression and treatment with the chemotherapeutic agent cisplatin leads to overt accumulation of DNA damage in cells devoid of Kaiso. Our data thus favor a model in which Kaiso promotes fast transcriptional activation of key cellular processes in cancer cells through binding of its non-canonical consensus site.

  • Open Access

    Kaiso mediates transcription and RNA splicing in colorectal carcinoma: role of BRCA1 in the Kaiso enhanceosome

    by Weifeng Luo, Manish K. Tripathi, Qi Liu, Lei Chen, Robert W. Cowan, Juliet M. Daniel, Chi Yan, Ann Richmond, Albert B. Reynolds

    Kaiso (ZBTB33) is a transcription factor involved in mitotic clonal expansion and tumorigenesis in association with Adenomatous Polyposis Coli (APC) loss of heterozygosity. ENCODE data show strong overlap of the Kaiso promoter-binding site—encode-derived Kaiso-binding site (eKBS) and many other transcription factors, including BRCA1. Here we sought to determine whether BRCA1 is a component of the Kaiso enhanceosome that regulates gene transcription. Using proximal ligation assays, immunoprecipitation followed by mass spectrometry, luciferase assays and ChIP-seq experiments, we evaluated the association between BRCA1 and Kaiso. Kaiso nuclear extract immunoprecipitation experiments revealed that Kaiso associates strongly with genes involved in RNA splicing and processing. When Kaiso was not crosslinked to DNA, BRCA1 was not detected among Kaiso-binding proteins. However, overexpression of BRCA1 increased Kaiso-mediated gene transcription in luciferase assays in a Kaiso-dependent manner. Comparison of BRCA1 ChIP-seq and Kaiso ChIP-seq data from HCT116 cells revealed both BRCA1 and Kaiso commonly bind to the promoters of 379 genes. The most enriched term associated with these genes where BRCA1 and Kaiso bind their promoters is metabolism of RNA. Disease processes associated with these BRCA1/Kaiso gene promoters indicate that BRCA1 is functionally linked to a Kaiso-directed programme of RNAP2-mediated gene transcription and likely associated with colorectal cancer development and maintenance.


  • Open Access

    When “One Size Fits All” Fits None: A Commentary on the Impacts of the“Draft Canadian Breast Cancer Screening Guidelines” on Racialized Populations in Canada

    by Beverley Osei, Gayathri Naganathan, Juliet M. Daniel, Supriya Kulkarni, Aisha Lofters, Yinka Oladele, Leila Springer, Mojola Omole

    Epidemiological data show racial and ethnic differences exist in breast cancer morbidity and mortality amongst Black, Indigenous, Asian, and Hispanic populations, with non-white females experiencing earlier age at diagnosis, more aggressive breast cancer subtypes and advanced cancer stages, and earlier mortality than white females. However, the current Canadian breast cancer screening guidelines recommend biannual screening for all females starting from age 50 to age 74 and suggest not to screen individuals aged 40–49. In May 2024, the Canadian Task Force for Preventative Health released updated draft breast cancer screening guidelines, maintaining such recommendations for screening. Both the existing and the proposed guidelines fail to account for the unique cancer burden amongst racialized populations in Canada and risk further perpetuation of existing racial and ethnic disparities by underscreening racialized females. This commentary will present data regarding racial disparities in cancer burden, highlighting the role social and biological factors play in impacting cancer risk and age of disease and presenting perspectives from stakeholder groups reflecting the impacts of current screening guidelines. Ultimately, we critique the current “one-size-fits-all” approach to breast cancer screening in Canada, emphasizing the need for adapted screening practices with the understanding that the current approaches overlook the needs of racialized Canadian populations.


  • Open Access

    Adherens junction proteins on the move—From the membrane to the nucleus in intestinal diseases

    by Lindyann R. Lessey, Shaiya C. Robinson, Roopali Chaudhary, Juliet M. Daniel

    The function and structure of the mammalian epithelial cell layer is maintained by distinct intercellular adhesion complexes including adherens junctions (AJs), tight junctions, and desmosomes. The AJ is most integral for stabilizing cell-cell adhesion and conserving the structural integrity of epithelial tissues. AJs are comprised of the transmembrane protein E-cadherin and cytoplasmic catenin cofactors (α, β, γ, and p120-catenin). One organ where malfunction of AJ is a major contributor to disease states is the mammalian intestine. In the intestine, cell-cell adhesion complexes work synergistically to maintain structural integrity and homeostasis of the epithelium and prevent its malfunction. Consequently, when AJ integrity is compromised in the intestinal epithelium, the ensuing homeostatic disruption leads to diseases such as inflammatory bowel disease and colorectal carcinoma. In addition to their function at the plasma membrane, protein components of AJs also have nuclear functions and are thus implicated in regulating gene expression and intracellular signaling. Within the nucleus, AJ proteins have been shown to interact with transcription factors such as TCF/LEF and Kaiso (ZBTB33), which converge on the canonical Wnt signaling pathway. The multifaceted nature of AJ proteins highlights their complexity in modulating homeostasis and emphasizes the importance of their subcellular localization and expression in the mammalian intestine. In this review, we summarize the nuclear roles of AJ proteins in intestinal tissues; their interactions with transcription factors and how this leads to crosstalk with canonical Wnt signaling; and how nuclear AJ proteins are implicated in intestinal homeostasis and disease.


  • Open Access

    Roads to Stat3 Paved with Cadherins

    by Hanad Adan, Juliet Daniel, Leda Raptis

    The engagement of cadherins, cell-to-cell adhesion proteins, triggers a dramatic increase in the levels and activity of the Rac/Cdc42 GTPases, through the inhibition of proteasomal degradation. This leads to an increase in transcription and secretion of IL6 family cytokines, activation of their common receptor, gp130, in an autocrine manner and phosphorylation of the signal transducer and activator of transcription-3 (Stat3) on tyrosine-705 by the Jak kinases. Stat3 subsequently dimerizes, migrates to the nucleus and activates the transcription of genes involved in cell division and survival. The Src oncogene also increases Rac levels, leading to secretion of IL6 family cytokines and gp130 activation, which triggers a Stat3-ptyr705 increase. Interestingly, at the same time, Src downregulates cadherins in a quantitative manner, while cadherins are required to preserve gp130 levels for IL6 family signalling. Therefore, a fine balance between Src527F/Rac/IL6 and Src527F/cadherin/gp130 levels is in existence, which is required for Stat3 activation. This further demonstrates the important role of cadherins in the activation of Stat3, through preservation of gp130 function. Conversely, the absence of cadherin engagement correlates with low Stat3 activity: In sparsely growing cells, both gp130 and Stat3-ptyr705 levels are very low, despite the fact that cSrc is active in the FAK (focal adhesion kinase)/cSrc complex, which further indicates that the engagement of cadherins is important for Stat3 activation, not just their presence. Furthermore, the caveolin-1 protein downregulates Stat3 through binding and sequestration of cadherins to the scaffolding domain of caveolin-1. We hypothesize that the cadherins/Rac/gp130 axis may be a conserved pathway to Stat3 activation in a number of systems. This fact could have significant implications in Stat3 biology, as well as in drug testing and development.


  • Open Access

    Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis

    by Shawn M Hercules, Meena Alnajar, Chen Chen, Stefan M Mladjenovic, Bolade Ajarat Shipeolu, Olga Perkovic, Greg R Pond, Lawrence Mbuagbaw, Kim Rm Blenman, Juliet M Daniel

    Objective: The aggressive triple-negative breast cancer (TNBC) subtype disproportionately affects women of African ancestry across the diaspora, but its frequency across Africa has not been widely studied. This study seeks to estimate the frequency of TNBC among African populations. Design: Systematic review and meta-analysis using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. Data sources: PubMed, EMBASE, African Journals Online and Web of Science were searched on 25 April 2021. Eligibility criteria for selecting studies: We included studies that use breast cancer tissue samples from indigenous African women with sample size of eligible participants ≥40 and full receptor status for all three receptors (oestrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2)) reported. Data extraction and synthesis: Two independent reviewers extracted data and assessed risk of bias using the modified assessment tool by Hoy et al. (2012) for prevalence studies. A random-effects meta-analysis was performed, and data were pooled using the inverse-variance method and logit transformation. Pooled frequencies were reported with 95% CIs calculated with the Clopper-Pearson method and heterogeneity quantified with I2 statistic. GRADE assessed the certainty of the evidence. Results: 1808 potentially eligible studies were identified of which 67 were included in the systematic review and 60 were included in the meta- analysis. Pooled TNBC frequency across African countries represented was estimated to be 27.0%; 95% CI: 24.0% to 30.2%, I2=94%. Pooled TNBC frequency was highest across West Africa, 45.7% (n=15, 95% CI: 38.8% to 52.8%, I2=91%) and lowest in Central Africa, 14.9% (n=1, 95% CI: 8.9 % to 24.1%). Estimates for TNBC were higher for studies that used Allred guidelines for ER/PR status compared with American Society of Clinical Oncology(ASCO)/College of American Pathologists(CAP) guidelines, and for studies that used older versions of ASCO/CAP guidelines for assessing HER2 status. Certainty of evidence was assessed to be very low using GRADE approach. Conclusion: TNBC frequency was variable with the highest frequency reported in West Africa. Greater emphasis should be placed on establishing protocols for assessing receptor status due to the variability among studies.


  • Open Access

    Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer

    by Shawn M. Hercules, Xiyu Liu, Blessing B. I. Bassey-Archibong, Desiree H. A. Skeete, Suzanne Smith Connell, Adetola Daramola, Adekunbiola A. Banjo, Godwin Ebughe, Thomas Agan, Ima-Obong Ekanem, et al.

    Purpose: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that disproportionately affects women of African ancestry (WAA) and is often associated with poor survival. Although there is a high prevalence of TNBC across West Africa and in women of the African diaspora, there has been no comprehensive genomics study to investigate the mutational profile of ancestrally related women across the Caribbean and West Africa.Methods: This multisite cross-sectional study used 31 formalin-fixed paraffin-embedded (FFPE) samples from Barbadian and Nigerian TNBC participants. High-resolution whole exome sequencing (WES) was performed on the Barbadian and Nigerian TNBC samples to identify their mutational profiles and comparisons were made to African American, European American and Asian American sequencing data obtained from The Cancer Genome Atlas (TCGA). Whole exome sequencing was conducted on tumors with an average of 382 × coverage and 4335 × coverage for pooled germline non-tumor samples.Results: Variants detected at high frequency in our WAA cohorts were found in the following genesNBPF12,PLIN4,TP53andBRCA1. In the TCGA TNBC cases, these genes had a lower mutation rate, except forTP53(32% in our cohort; 63% in TCGA-African American; 67% in TCGA-European American; 63% in TCGA-Asian). For all altered genes, there were no differences in frequency of mutations between WAA TNBC groups including the TCGA-African American cohort. For copy number variants, high frequency alterations were observed inPIK3CA, TP53, FGFR2andHIF1ANgenes.Conclusion: This study provides novel insights into the underlying genomic alterations in WAA TNBC samples and shines light on the importance of inclusion of under-represented populations in cancer genomics and biomarker studies.